JP2025507472A5 - - Google Patents
Info
- Publication number
- JP2025507472A5 JP2025507472A5 JP2023580943A JP2023580943A JP2025507472A5 JP 2025507472 A5 JP2025507472 A5 JP 2025507472A5 JP 2023580943 A JP2023580943 A JP 2023580943A JP 2023580943 A JP2023580943 A JP 2023580943A JP 2025507472 A5 JP2025507472 A5 JP 2025507472A5
- Authority
- JP
- Japan
- Prior art keywords
- hcov
- cov
- pharmaceutically acceptable
- sars
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210199543 | 2022-03-01 | ||
| CN202210199543.5 | 2022-03-01 | ||
| PCT/CN2023/076078 WO2023165334A1 (zh) | 2022-03-01 | 2023-02-15 | 酮酰胺类衍生物及其制药用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025507472A JP2025507472A (ja) | 2025-03-21 |
| JP2025507472A5 true JP2025507472A5 (enExample) | 2025-12-17 |
Family
ID=87830006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023580943A Pending JP2025507472A (ja) | 2022-03-01 | 2023-02-15 | ケトアミド系誘導体及びその製薬における使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250064789A1 (enExample) |
| EP (1) | EP4488264A4 (enExample) |
| JP (1) | JP2025507472A (enExample) |
| CN (1) | CN116693447B (enExample) |
| WO (1) | WO2023165334A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022306289A1 (en) | 2021-07-09 | 2024-01-18 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| JP2025507472A (ja) * | 2022-03-01 | 2025-03-21 | ウエストバック バイオファーマ カンパニー リミテッド | ケトアミド系誘導体及びその製薬における使用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0650368A1 (en) * | 1992-06-24 | 1995-05-03 | Cortex Pharmaceuticals, Inc. | Use of calpain inhibitors in the inhibition and treatment of medical conditions associated with increased calpain activity |
| US5514694A (en) * | 1992-09-21 | 1996-05-07 | Georgia Tech Research Corp | Peptidyl ketoamides |
| JPH08208462A (ja) * | 1994-11-24 | 1996-08-13 | Takeda Chem Ind Ltd | カテプシンｌ阻害剤 |
| AU4489397A (en) * | 1996-10-31 | 1998-05-22 | Alcon Laboratories, Inc. | The use of calpain inhibitors to treat ocular neural pathology |
| WO1999054320A1 (de) * | 1998-04-20 | 1999-10-28 | Basf Aktiengesellschaft | Neue heterocyclisch substituierte amide mit cystein-protease hemmender wirkung |
| US20020107266A1 (en) * | 2000-12-12 | 2002-08-08 | Marguerita Lim-Wilby | Compounds, compositions and methods for treatment of parasitic infections |
| EP1553964A4 (en) * | 2002-09-25 | 2009-08-12 | Georgia Tech Res Inst | KETOAMID INHIBITORS IN CHRONIC NERVE DISEASES |
| US8236798B2 (en) * | 2009-05-07 | 2012-08-07 | Abbott Gmbh & Co. Kg | Carboxamide compounds and their use as calpain inhibitors |
| US8598211B2 (en) * | 2009-12-22 | 2013-12-03 | Abbvie Inc. | Carboxamide compounds and their use as calpain inhibitors IV |
| GB201001070D0 (en) * | 2010-01-22 | 2010-03-10 | St George's Hospital Medical School | Theraputic compounds and their use |
| WO2018064119A1 (en) * | 2016-09-28 | 2018-04-05 | Blade Therapeutics, Inc. | Calpain modulators and therapeutic uses thereof |
| AU2021254045A1 (en) * | 2020-04-10 | 2022-10-13 | Cocrystal Pharma, Inc. | Inhibitors of norovirus and coronavirus replication |
| PH12022553378A1 (en) * | 2020-06-10 | 2024-03-25 | Univ Leuven Kath | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections |
| CN115960088B (zh) * | 2020-07-31 | 2024-07-26 | 四川大学 | 一种新型冠状病毒主蛋白酶的抑制剂及其制备方法和用途 |
| CN114057702B (zh) * | 2020-07-31 | 2022-09-30 | 四川大学 | 一种新型冠状病毒主蛋白酶的抑制剂及其制备方法和用途 |
| US20240083885A1 (en) * | 2020-12-04 | 2024-03-14 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for inhibiting m pro protease activity and for preventing and treating sars-cov-2 infection |
| WO2022265577A2 (en) * | 2021-06-15 | 2022-12-22 | Agency For Science, Technology And Research | Coronavirus enzyme modulators, methods of synthesis and uses thereof |
| JP2023000996A (ja) * | 2021-06-18 | 2023-01-04 | ラクオリア創薬株式会社 | プロテアーゼ阻害剤としてのケトアミド誘導体 |
| JP2025507472A (ja) * | 2022-03-01 | 2025-03-21 | ウエストバック バイオファーマ カンパニー リミテッド | ケトアミド系誘導体及びその製薬における使用 |
-
2023
- 2023-02-15 JP JP2023580943A patent/JP2025507472A/ja active Pending
- 2023-02-15 US US18/723,545 patent/US20250064789A1/en active Pending
- 2023-02-15 EP EP23762735.1A patent/EP4488264A4/en active Pending
- 2023-02-15 WO PCT/CN2023/076078 patent/WO2023165334A1/zh not_active Ceased
- 2023-02-17 CN CN202310131329.0A patent/CN116693447B/zh active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023017050A5 (enExample) | ||
| PE20242299A1 (es) | Composiciones agonistas de gip/glp1 | |
| ZA202400988B (en) | Aak1 inhibitor and use thereof | |
| JP2025507472A5 (enExample) | ||
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2007533686A5 (enExample) | ||
| EA202092168A1 (ru) | Применение фавипиравира в лечении коронавирусной инфекции | |
| MX2009001660A (es) | Compuestos de 2,5-dihidroxibenceno para el tratamiento de psoriasis. | |
| NO341573B1 (no) | Faste formuleringer av ospemifen og fremgangsmåte for fremstilling av ospemifen | |
| BRPI0413186A (pt) | composição de fexofenadina e processo para preparação da mesma | |
| JOP20210185A1 (ar) | مركبات هالو-آلِّيلامين واستخدامها | |
| AR061166A1 (es) | Composiciones farmaceuticas para la liberacion sostenida de fenilferina | |
| CO2022008616A2 (es) | Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma | |
| MXPA05005781A (es) | Combinacion de ibuprofeno y oxicodona para alivio de dolor agudo. | |
| NO20082181L (no) | Formuleringer av Fispemifen | |
| CL2024003616A1 (es) | Composición farmacéutica oral y uso para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| SE0401655D0 (sv) | New compounds | |
| CO2026000726A2 (es) | Una forma farmacéutica sólida de dosificación bucodispersable de safinamida | |
| AR039221A1 (es) | Combinaciones de epinastina, belladona y pseudoefedrina como formulaciones farmaceuticas | |
| AR127966A1 (es) | Formulaciones tópicas de inhibidores de pi3k-delta | |
| MX2021003670A (es) | Derivados biciclicos como moduladores del receptor gabaa a5. | |
| UY30126A1 (es) | Una nueva sal farmaceuticamente aceptable de 2-hidroxi-3-(5-(morfolin-4-ilmetil)-piridin-2-l)1h-indol-5-carbonitrilo, procedimientos para su preparacion, composiciones que la contienen yaplicaciones | |
| UY29445A1 (es) | Composiciones para la transmisión transmucosa oral de la metformina | |
| AR087240A2 (es) | Composiciones farmaceuticas que tienen epinastina y pseudoefedrina | |
| EA200500672A1 (ru) | Содержащие альфузозин композиции с отсроченным высвобождением |